Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;76(5):642-8.
doi: 10.1111/bcp.12068.

Early QT assessment--how can our confidence in the data be improved?

Affiliations
Review

Early QT assessment--how can our confidence in the data be improved?

Borje Darpo et al. Br J Clin Pharmacol. 2013 Nov.

Abstract

Exposure-response (ER) analysis has emerged as an important tool to interpret QT data from thorough QT (TQT) studies and allows the prediction of effects in the targeted patient population. Recently, ER analysis has also been applied to data from early clinical pharmacology studies, such as single and multiple ascending dose studies, in which high plasma concentrations are often achieved. In line with this, there is an on-going discussion between sponsors, academicians and regulators on whether 'early QT assessment' can provide sufficiently high confidence in assessment of QT prolongation to replace the TQT study. In this article, we discuss how QT assessment can be applied to early clinical studies ('early QT assessment') and what we believe is needed to achieve the same high confidence in the data as we currently obtain from data from the TQT study. The power to exclude a QTc effect exceeding 10 ms in small sample sizes using ER analysis will be discussed and compared with time-matched analysis, as described in the ICH E14 guidance. Two examples of early QT assessment are shared; one negative and one positive, and the challenge in terms of demonstrating assay sensitivity in the absence of a pharmacological positive control will be discussed. Finally, we describe a recent research proposal, which may generate data to support the replacement of the TQT study with data from QT assessment in early phase 1 studies.

Keywords: Early QT assessment; PK/PD thorough QT study; QT; QT/QTc; healthy volunteers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The model based estimate (solid black line) with 90% CI (grey shaded area) is shown across the range of plasma concentrations observed in the SAD study. The horizontal red line shows the plasma concentration divided into deciles and the vertical, red bars show the observed ΔΔQTcF with 90% CI within each plasma concentration decile (plotted at the median concentration of each decile). As shown by the upper bound of the 90% CI, a drug-induced effect on the QTc interval exceeding 10 ms could be excluded at all observed plasma concentrations. formula image, median concentration quantiles; formula image, mean (90% CI) predicted QTcF prolongation
Figure 2
Figure 2
A emonstrated with an increase of approximately 1.85 ms (90% CI ± 0.45) per 100 ng ml−1 increase in plasma concentration. At plasma concentrations around 1 μg ml−1, the predicted QTc effect is around 18 ms with an upper bound of the CI of 23 ms. formula image, observed QTcF (mean ± 90% CI); formula image, model predicted effect on QTcF (mean ± 90% CI)

Similar articles

Cited by

References

    1. ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. Available at: http://www.ich.org/cache/compo/276-254-1.html (last accessed 21 December 2012) - PubMed
    1. Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf. 2005;28:115–125. - PubMed
    1. Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK. Electrocardiographic assessment for therapeutic proteins – scientific discussion. Am Heart J. 2010;160:627–634. - PubMed
    1. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827–836. 836. - PubMed
    1. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2009;159:49–57. - PMC - PubMed

MeSH terms

LinkOut - more resources